Pharma companies in consonance with implementing revised drug

Image
Press Trust of India New Delhi
Last Updated : Oct 30 2014 | 6:50 PM IST
The Centre today told the Delhi High Court that pharmaceutical companies, including Novartis India Limited and Cipla Ltd, appear to be in "consonance" with implementation of the revised drug pricing and the two sides are "very close" to resolving the dispute.
Petitions were filed by pharmaceutical companies and an association of medicine manufacturing companies challenging the government's new drug pricing order that asked them to slash prices of 348 medicines.
The Centre informed the bench of Justice B D Ahmed and Justice Vibhu Bakhru that they have held two meetings with the representatives of pharma companies and are very close to resolving the issue.
"The company representatives, after deliberation with each other, appear to be in consonance with implementation of the notified prices from date of notification in sale of all stocks.
"They were requested to issue price list in Form-V as per the provision of...Drug Price Control Order (DPCO), 2013 which they also appear to be in agreement," Central Government Standing Counsel Jasmeet Singh
"The company representatives mentioned difficulties on labeling aspect particularly on vials in respect of existing stock in the market," as per the brief note of the meeting held between the pharma firms and the National Pharmaceutical Pricing Authority (NPPA).
The representatives of pharma companies held meetings with the Director of NPPA on the court's direction issued on September 9 to settle the matter "once and for ever".
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 30 2014 | 6:50 PM IST

Next Story